Related Experiment Video
Updated: May 6, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
38.4K
Radiation recall dermatitis induced by pazopanib
Arun Azad1, Claire Maddison, Josephine Stewart
1Joint Austin-Ludwig Oncology Unit, Austin Health, Melbourne, Australia.
Onkologie
|November 7, 2013
Summary
Pazopanib, used for advanced kidney cancer, may trigger radiation recall dermatitis (RRD). This first reported case highlights the need for awareness in patients receiving radiotherapy after pazopanib treatment.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Pazopanib is an approved tyrosine kinase inhibitor for advanced clear cell renal cell carcinoma (RCC).
- Radiation recall dermatitis (RRD) is an adverse skin reaction to radiotherapy.
- No prior reports linked pazopanib to RRD.
Observation:
- A patient with metastatic RCC received pazopanib and subsequent radiotherapy to bone metastases.
- Two weeks post-radiotherapy, the patient developed a localized, pruritic, erythematous rash.
- The rash distribution corresponded to the radiotherapy fields.
Findings:
- The patient was diagnosed with pazopanib-induced RRD.
- Treatment with oral prednisolone led to rash resolution.
- The patient tolerated continued pazopanib therapy without RRD recurrence.
Implications:
- This is the first reported case of pazopanib triggering RRD.
- Clinicians should consider pazopanib as a potential cause of RRD in RCC patients.
- Awareness is crucial for managing patients undergoing radiotherapy and pazopanib treatment.
